Active Surveillance in Non-Muscle Invasive Bladder Cancer

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala


Non-muscle invasive bladder cancer (NMIBC) represents approximately 70% of all incident cases of bladder cancer (Large et al.). Consensus guidelines differ on risk definition and in management. A systematic review relating to active surveillance in non-muscle invasive bladder cancer was conducted. This was to identify references relating to bladder cancer and en-bloc resection. The search strategy aimed to identify all references related to bladder cancer AND screening. Search terms used were as follows: (Bladder cancer) AND (low risk) AND (Active Surveillance) . This chapter covers systematic review results.


  1. Gofrit ON, Shapiro A. Active surveillance of low grade bladder tumors. Arch Ital Urol Androl. 2008;80(4):132–5.PubMedGoogle Scholar
  2. Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. The long-term outcome in patients with NMI transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int. 1999;83(9):957–63.CrossRefGoogle Scholar
  3. Hernández V, Alvarez M, de la Peña E, Amaruch N, Martín MD, de la Morena JM, Gómez V, Llorente C. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology. 2009;73(6):1306–10.CrossRefGoogle Scholar
  4. Hernández V, Llorente C, de la Peña E, Pérez-Fernández E, Guijarro A, Sola I. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016;34(4):165.e19–23.CrossRefGoogle Scholar
  5. Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, Saita A, et al. Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the bias project. J Urol. 2018;199(2):401–6.CrossRefGoogle Scholar
  6. Hurle R, Pasini L, Lazzeri M, Colombo P, Buffi N, Lughezzani G, Casale P, Morenghi E, Peschechera R, Zandegiacomo S, Benetti A, Saita A, Cardone P, Guazzoni G. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the bladder cancer Italian active surveillance (BIAS) project. BJU Int. 2016;118(6):935–9.CrossRefGoogle Scholar
  7. Mays N, Pope, C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(Suppl. 1): 6–20.CrossRefGoogle Scholar
  8. Miyake M, Fujimoto K, Hirao Y. Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol. 2016;57(Suppl. 1):S4–13.CrossRefGoogle Scholar
  9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ. 2009;339(7716):332–6.CrossRefGoogle Scholar
  10. Tiu A, Jenkins LC, Soloway MS. Active surveillance for low-risk bladder cancer. Urol Oncol. 2014;32(1):33.e7–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations